EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease

Nikhil Y Patil iD, Jacob E Friedman iD, Aditya D Joshi

Receptors · 2023

DOI: 10.3390/receptors2010001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Receptors, 2023. Verfasst von Nikhil Y Patil und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health-National Institutes of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Numerous nuclear receptors including farnesoid X receptor, liver X receptor, peroxisome proliferator-activated receptors, pregnane X receptor, hepatic nuclear factors have been extensively studied within the context of non-alcoholic fatty liver disease (NAFLD). Following the first description of the Aryl hydrocarbon Receptor (AhR) in the 1970s and decades of research which unveiled its role in toxicity and pathophysiological processes, the functional significance of AhR in NAFLD has not been completely decoded. Recently, multiple research groups have utilized a plethora of in vitro and in vivo models that mimic NAFLD pathology to investigate the functional significance of AhR in fatty liver disease. This review provides a comprehensive account of studies describing both the beneficial and possible detrimental role of AhR in NAFLD. A plausible reconciliation for the paradox indicating AhR as a ‘double-edged sword’ in NAFLD is discussed. Finally, understanding AhR ligands and their signaling in NAFLD will facilitate us to probe AhR as a potential drug target to design innovative therapeutics against NAFLD in the near future.

Schlagwörter

Stichwörter der Autor:innen

2,3,7,8-tetrachlorodibenzo-p-dioxinAhRCD36Cyp1a1NAFLDNASHTCDDXREaryl hydrocarbon receptorcluster of differentiation 36cytochrome p450 1a1non-alcoholic fatty liver diseasenon-alcoholic steatohepatitisxenobiotic response element

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
  • Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.

ORCID-Profile: Nikhil Y Patil, Jacob E Friedman

Förderung

  • NIDDK NIH HHS
  • National Institutes of Health-National Institutes of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Patil, N. Y., Friedman, J. E., & Joshi, A. D. (2023). Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease. Receptors. https://doi.org/10.3390/receptors2010001

Vancouver

Patil NY, Friedman JE, Joshi AD. Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease. Receptors. 2023. doi:10.3390/receptors2010001

BibTeX
@article{Patil2023,
  author = {Patil, Nikhil Y and Friedman, Jacob E and Joshi, Aditya D},
  title = {Role of Hepatic Aryl Hydrocarbon Receptor in Non-Alcoholic Fatty Liver Disease},
  journal = {Receptors},
  year = {2023},
  doi = {10.3390/receptors2010001}
}
Kostenlos starten →